Cargando…

Calretinin as a blood-based biomarker for mesothelioma

BACKGROUND: Malignant mesothelioma (MM) is a deadly cancer mainly caused by previous exposure to asbestos. With a latency period up to 50 years the incidence of MM is still increasing, even in countries that banned asbestos. Secondary prevention has been established to provide persons at risk regula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnen, Georg, Gawrych, Katarzyna, Raiko, Irina, Casjens, Swaantje, Pesch, Beate, Weber, Daniel G., Taeger, Dirk, Lehnert, Martin, Kollmeier, Jens, Bauer, Torsten, Musk, Arthur W., Robinson, Bruce W. S., Brüning, Thomas, Creaney, Jenette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450182/ https://www.ncbi.nlm.nih.gov/pubmed/28558669 http://dx.doi.org/10.1186/s12885-017-3375-5

Ejemplares similares

Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers
por: Johnen, Georg, et al.
Publicado: (2018)

Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma
por: Weber, Daniel G., et al.
Publicado: (2017)

Determinants of plasma calretinin in patients with malignant pleural mesothelioma
por: Lehnert, Martin, et al.
Publicado: (2020)

Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study
por: Casjens, Swaantje, et al.
Publicado: (2017)

Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis
por: Weber, Daniel G., et al.
Publicado: (2014)

Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies
por: Weber, Daniel G., et al.
Publicado: (2020)

Re-evaluation of potential predictors of calretinin and mesothelin in a population-based cohort study using assays for the routine application in clinical medicine
por: Casjens, Swaantje, et al.
Publicado: (2021)

Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case–control study
por: Weber, Daniel Gilbert, et al.
Publicado: (2019)

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany
por: Rihs, Hans-Peter, et al.
Publicado: (2022)

Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients
por: Raiko, Irina, et al.
Publicado: (2010)

Assessment of miR-103a-3p in leukocytes—No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis
por: Jiménez-Ramírez, Carmina, et al.
Publicado: (2022)

Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer
por: Weber, Daniel Gilbert, et al.
Publicado: (2013)

Exploring solid-phase proximity ligation assay for survivin detection in urine
por: Gleichenhagen, Jan, et al.
Publicado: (2022)

NOTCH1, HIF1A and Other Cancer-Related Proteins in Lung Tissue from Uranium Miners—Variation by Occupational Exposure and Subtype of Lung Cancer
por: Pesch, Beate, et al.
Publicado: (2012)

Assessment of mRNA and microRNA Stabilization in Peripheral Human Blood for Multicenter Studies and Biobanks
por: Weber, Daniel Gilbert, et al.
Publicado: (2010)

Blood‐based detection of lung cancer using cysteine‐rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker: a pilot study
por: Ac\ˇkar, Lucija, et al.
Publicado: (2021)

Evaluation of a New Survivin ELISA and UBC(®) Rapid for the Detection of Bladder Cancer in Urine
por: Gleichenhagen, Jan, et al.
Publicado: (2018)

Cancer Incidence and Mortality in Firefighters
por: Casjens, Swaantje, et al.
Publicado: (2020)

Cancer risks of firefighters: a systematic review and meta-analysis of secular trends and region-specific differences
por: Casjens, Swaantje, et al.
Publicado: (2020)

Author’s reply to: cancer risks of firefighters: a systematic review and meta‑analysis of secular trends and region‑specific differences
por: Casjens, Swaantje, et al.
Publicado: (2021)

Discovery of new biomarkers for malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2015)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)

Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms
por: Morré, D. James, et al.
Publicado: (2016)

Performance of Survivin mRNA as a Biomarker for Bladder Cancer in the Prospective Study UroScreen
por: Johnen, Georg, et al.
Publicado: (2012)

How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies
por: Robinson, Bruce W.S., et al.
Publicado: (2022)

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population
por: Aguilar-Madrid, Guadalupe, et al.
Publicado: (2018)

Auto-Antibodies to β-F1-ATPase and Vimentin in Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2011)

Chromosomal alterations in exfoliated urothelial cells from bladder cancer cases and healthy men: a prospective screening study
por: Bonberg, Nadine, et al.
Publicado: (2014)

Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum
por: Weber, Daniel Gilbert, et al.
Publicado: (2010)

Serum Calretinin as a Biomarker in Malignant Mesothelioma
por: Zupanc, Cita, et al.
Publicado: (2021)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo
por: Greening, David W., et al.
Publicado: (2016)

MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
por: Birnie, Kimberly A., et al.
Publicado: (2019)

Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma
por: Kresoja-Rakic, Jelena, et al.
Publicado: (2017)

Hyaluronic acid in viscous malignant mesothelioma pleural effusion
por: Cheah, Hui Min, et al.
Publicado: (2020)

Digital PCR for the Analysis of MYC Copy Number Variation in Lung Cancer
por: Brik, Alexander, et al.
Publicado: (2020)

p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression
por: Creaney, J, et al.
Publicado: (2001)

Impact of occupational SARS-CoV-2 risk on the mental distress of non-healthcare employees in Germany: Swaantje Casjens
por: Casjens, S, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_njeeral0nr8q87k4rk2mdqckq9